The promotion of Dr. Vishwa Srivastava to president and the appointment of Gary Lo as chief financial officer at SS Innovations International (NASDAQ: SSII) come at a pivotal moment for the surgical robotics developer, as it seeks to expand the global footprint of its SSi Mantra system while managing critical regulatory reviews in the United States and Europe. Srivastava, previously CEO of the company’s Asia Pacific operations, will now focus on building the U.S. business and leading global operations. Both executives are based in the United States, a detail that underscores the company’s commitment to its home market even as it maintains a significant R&D presence in India.
The timing of these appointments is notable because SS Innovations is currently responding to questions from the U.S. Food and Drug Administration regarding its 510(k) premarket notification for the SSi Mantra. Securing FDA clearance is essential for commercializing the system in the U.S., and Srivastava’s new role places him at the center of that effort. Simultaneously, the company is pursuing CE marking certification in the European Union, which would open access to another major market. Lo’s three decades of financial leadership experience, including in the medical technology sector, will be crucial for managing the costs and strategic growth associated with these regulatory processes and international expansion.
Beyond regulatory matters, SS Innovations is finalizing a pipeline of additional health care technologies at its research and development facility in India, with plans to introduce them in the coming months. This suggests the company is not relying solely on the SSi Mantra but is actively diversifying its product portfolio to strengthen its competitive position. The SSi Mantra itself is a modular, multi-arm surgical robotic system that has been clinically validated in India across more than 190 different types of surgical procedures, including cardiac surgery. Its features include 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and the optional SSi MantrAsana tele-surgeon console for telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries.
These leadership changes matter because they signal a shift from development and clinical validation toward commercialization and market access. By placing Srivastava, with his experience in the Asia Pacific region, in charge of global operations and the U.S. business, SS Innovations is betting that his operational expertise can translate into successful market penetration. Lo’s financial expertise will be needed to navigate the capital-intensive nature of regulatory approvals and global expansion. For investors and industry observers, the appointments provide a clearer picture of how the company intends to execute its strategy amid the uncertainties of FDA review and European certification.
For more information, visit the company’s website at ssinnovations.com or its LinkedIn page. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.


